Lehigh Valley Health Network LVHN Scholarly Works

Research Scholars Poster Presentation

Evaluation of the Implementation of Rapid Cerebral Spinal Fluid Diagnostic Test for Meningitis and Encephalitis at a Large Academic Institution

Max Stempel Max.Stempel@lvhn.org

Amy Slenker MD Lehigh Valley Health Network, amy_k.slenker@lvhn.org

Follow this and additional works at: https://scholarlyworks.lvhn.org/research-scholars-posters Let us know how access to this document benefits you

Published In/Presented At

Stempel, M. Slenker, A. (2019, August). *Evaluation of the Implementation of Rapid Cerebral Spinal Fluid Diagnostic Test for Meningitis and Encephalitis at a Large Academic Institution*. poster Presented at: LVHN Research Scholar Program Poster Session, Lehigh Valley Health Network, Allentown, PA.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Evaluation of the Implementation of Rapid Cerebral Spinal Fluid Diagnostic Test for Meningitis and Encephalitis at a Large Academic Institution Max Stempel, Amy Slenker, MD

Background

- Meningitis and encephalitis are central nervous system (CNS) infectious diseases associated with significant morbidity and mortality in adult populations.
- Traditional approaches of culture and pathogenspecific polymerase chain reaction (PCR) tests are limited by slow turnaround time and low diagnostic yield.
- The FilmArray Meningitis and Encephalitis (M/E) panel is a multiplex PCR test targeting a combination of 14 viruses, bacteria, and yeasts.
- The M/E panel was first introduced at LVHN in February, 2016.

Objectives

This study aims to determine how the M/E panel affects clinical outcomes including: time to diagnosis, appropriate antibiotic deescalation, days of therapy, and mortality.

Methods


Retrospective analysis of patients with CSF culture from 2/23/2015 to 2/22/2016 (Pre-Intervention) and M/E panel and CSF culture from 2/23/2016 to 2/22/2017 (Post-Intervention).

Review EMR for: demographics, length of stay, type of CSF studies, CSF collection date and time, CSF result date and time, antibiotics administered, antibiotic initiation and discontinuation date and time.

Perform descriptive statistics to compare the pre and post-intervention groups regarding: time to diagnosis, time to antibiotic deescalation, days of therapy, mortality.

Lehigh Valley Health Network, Allentown, Pennsylvania

Results



	Pre-group (N=23)	Post-group (N=20)
ean Time to rgeted Antibiotic D)	32.9 (25.9)	27.7 (32.2)
ean Time to agnosis in Hours D)	39.1 (40.3)	21.2 (39.0)
ean # CSF Tests dered (Range)	5.0 (2-10)	2.9 (2-5)
ean Length of ay Days (Range)	7.6 (1-28)	9.0 (3-52)

- M/E panel.

Conclusions/Recommendations

- results
- and mortality.

References/Acknowledgments

1. Messacar K, Breazeale G, Robinson CC et al. Potential clinical impact of the film array meningitis encephalitis panel in children with suspected central nervous system infections. Diagnostic Microbiology & Infectious Disease, 2016-09-01, Volume 86, Issue 1, Pages 118-120

2. Leber AL, Everhart K, Balada-Llasat J-M et al. Multicenter evaluation of the BioFire FilmArray meningitis/encephalitis panel fo the detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016; 54:2251-2261. 3. Kupila L, Vuorinen T, Vainionpää R et al. Etiology of aseptic meningitis and encephalitis in an adult population. *Neurology*. 2006; 66(1):75. 4. BioFire Diagnostics. 2015. FilmArray Meningitis/Encephalitis (ME) Panel instruction booklet RF-Y-ASY-0118. BioFire

Diagnostics, Salt Lake City, UT.

Special thanks to Health Network Laboratories (HNL) for their assistance with data and cost/charge information.



Results/Discussion

• Time to diagnosis decreased in the postintervention group for all pathogens included on the

 The post-intervention group had a reduced time from antibiotic initiation to discontinuation (70.0 h vs 81.7 h) and reduced antibiotic days of therapy (2.9 d vs 3.4 d) for negative CSF results

The post-intervention group had an overall decreased mean time to targeted therapy (27.7 h vs. 32.9 h) and reduced mean time to diagnosis (21.2 h vs. 39.1 h) for positive CSF results.

• The post-intervention group had a reduced average number of CSF tests (3.6 vs. 4.7).

• Notably, this translated into an increase in the average patient charge: \$1,339.79 vs. \$1,458.45, but a decrease in the average supply cost (\$434.26 vs \$314.29) in the post-intervention group.

The implementation of the M/E panel has resulted in improved time to diagnosis, time to antibiotic deescalation for negative CSF tests and time to targeted antibiotic therapy for positive CSF test

• Future research using a larger sample size is needed to determine if there is a change in outcomes data including: length of stay, ICU stay,

